Rhumbline Advisers Raises Stake in Twist Bioscience Co. (NASDAQ:TWST)

Rhumbline Advisers lifted its holdings in shares of Twist Bioscience Co. (NASDAQ:TWST) by 2.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 91,393 shares of the company’s stock after purchasing an additional 2,339 shares during the quarter. Rhumbline Advisers owned about 0.15% of Twist Bioscience worth $4,247,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently bought and sold shares of TWST. Van ECK Associates Corp increased its holdings in shares of Twist Bioscience by 56.4% in the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock valued at $34,000 after acquiring an additional 267 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Twist Bioscience by 2.3% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,243 shares of the company’s stock valued at $734,000 after buying an additional 363 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Twist Bioscience by 21.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock valued at $98,000 after buying an additional 381 shares during the period. D.A. Davidson & CO. raised its holdings in Twist Bioscience by 3.5% during the third quarter. D.A. Davidson & CO. now owns 19,618 shares of the company’s stock worth $886,000 after purchasing an additional 664 shares during the last quarter. Finally, Stifel Financial Corp raised its holdings in shares of Twist Bioscience by 11.8% in the third quarter. Stifel Financial Corp now owns 6,967 shares of the company’s stock worth $315,000 after acquiring an additional 734 shares during the last quarter.

Insiders Place Their Bets

In other news, Director Robert Chess sold 3,504 shares of the company’s stock in a transaction dated Thursday, December 5th. The stock was sold at an average price of $51.85, for a total value of $181,682.40. Following the transaction, the director now owns 21,641 shares in the company, valued at $1,122,085.85. This represents a 13.94 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Adam Laponis sold 5,886 shares of the stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $43.26, for a total value of $254,628.36. Following the completion of the transaction, the chief financial officer now owns 110,096 shares in the company, valued at $4,762,752.96. This represents a 5.07 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 37,180 shares of company stock worth $1,821,971. Company insiders own 3.01% of the company’s stock.

Wall Street Analysts Forecast Growth

TWST has been the subject of a number of recent analyst reports. Wolfe Research initiated coverage on Twist Bioscience in a research report on Friday, December 13th. They issued an “outperform” rating and a $60.00 price objective for the company. JPMorgan Chase & Co. lifted their price target on shares of Twist Bioscience from $35.00 to $40.00 and gave the company an “underweight” rating in a research report on Tuesday, February 4th. Robert W. Baird boosted their target price on shares of Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 4th. Barclays set a $58.00 price target on shares of Twist Bioscience and gave the stock an “overweight” rating in a research note on Monday, February 3rd. Finally, TD Cowen reiterated a “buy” rating and set a $58.00 target price on shares of Twist Bioscience in a research note on Tuesday, November 26th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $54.40.

Twist Bioscience Stock Performance

TWST stock opened at $38.82 on Friday. The company has a market capitalization of $2.32 billion, a P/E ratio of -11.49 and a beta of 1.87. The company has a 50-day simple moving average of $47.64 and a 200 day simple moving average of $45.62. Twist Bioscience Co. has a fifty-two week low of $27.41 and a fifty-two week high of $60.90. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.09. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The company had revenue of $88.70 million during the quarter, compared to the consensus estimate of $86.96 million. During the same period in the prior year, the company earned ($0.75) EPS. Twist Bioscience’s revenue was up 24.1% on a year-over-year basis. Sell-side analysts predict that Twist Bioscience Co. will post -2.12 earnings per share for the current fiscal year.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.